Gaboxadol HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525150

CAS#: 85118-33-8 (HCl)

Description: Gaboxadol, also known as THIP, OV-101; Lu-02-030; MK-0928; Lu-02030, is a GABA agonist. It is an inhibitor of GABA uptake systems. Gaboxadol can also be a non-opioid analgesic and a novel type of hypnotic.

Chemical Structure

img
Gaboxadol HCl
CAS# 85118-33-8 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 525150
Name: Gaboxadol HCl
CAS#: 85118-33-8 (HCl)
Chemical Formula: C6H9ClN2O2
Exact Mass: 140.06
Molecular Weight: 176.600
Elemental Analysis: C, 40.81; H, 5.14; Cl, 20.07; N, 15.86; O, 18.12

Price and Availability

Size Price Availability Quantity
25mg USD 150
50mg USD 250
100mg USD 450
200mg USD 850
500mg USD 1750
1g USD 2950
2g USD 4950
5g USD 7950
Bulk inquiry

Synonym: Gaboxadol; OV-101; Lu-02-030; MK-0928; Lu-02030; OV-101; Lu02-030; MK0928; Lu02030. THIP

IUPAC/Chemical Name: 4,5,6,7-Tetrahydroisoxazolo(5,4-c)pyridin-3(2H)-one monohydrochloride

InChi Key: ZDZDSZQYRBZPNN-UHFFFAOYSA-N

InChi Code: InChI=1S/C6H8N2O2.ClH/c9-6-4-1-2-7-3-5(4)10-8-6;/h7H,1-3H2,(H,8,9);1H

SMILES Code: O=C1NOC2=C1CCNC2.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#64603-91-4 (Gaboxadol freebase) CAS#85118-33-8 (Gaboxadol hydrochloride salt) CAS#65202-63-3 (Gaboxadol hydrobromide salt)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 176.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Silverman NS, Popp S, Vialou V, Astafurov K, Nestler EJ, Dow-Edwards D. Effects of gaboxadol on the expression of cocaine sensitization in rats. Exp Clin Psychopharmacol. 2016 Apr;24(2):131-41. doi: 10.1037/pha0000069. Epub 2016 Feb 22. PubMed PMID: 26901591.

2: Zanettini C, Pressly JD, Ibarra MH, Smith KR, Gerak LR. Comparing the discriminative stimulus effects of modulators of GABAA receptors containing α4-δ subunits with those of gaboxadol in rats. Psychopharmacology (Berl). 2016 May;233(10):2005-13. doi: 10.1007/s00213-016-4243-8. Epub 2016 Feb 22. PubMed PMID: 26900079.

3: Kesisoglou F, Balakrishnan A, Manser K. Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption. J Pharm Sci. 2016 Feb;105(2):722-8. doi: 10.1002/jps.24674. Epub 2016 Jan 11. PubMed PMID: 26457884.

4: Ramaker MJ, Strong-Kaufman MN, Ford MM, Phillips TJ, Finn DA. Effect of nucleus accumbens shell infusions of ganaxolone or gaboxadol on ethanol consumption in mice. Psychopharmacology (Berl). 2015 Apr;232(8):1415-26. doi: 10.1007/s00213-014-3777-x. Epub 2014 Oct 25. PubMed PMID: 25342197; PubMed Central PMCID: PMC4412309.

5: Fritz BM, Boehm SL 2nd. Site-specific microinjection of Gaboxadol into the infralimbic cortex modulates ethanol intake in male C57BL/6J mice. Behav Brain Res. 2014 Oct 15;273:8-15. doi: 10.1016/j.bbr.2014.07.020. Epub 2014 Jul 18. PubMed PMID: 25043731; PubMed Central PMCID: PMC4152776.

6: Ramaker MJ, Ford MM, Phillips TJ, Finn DA. Differences in the reinstatement of ethanol seeking with ganaxolone and gaboxadol. Neuroscience. 2014 Jul 11;272:180-7. doi: 10.1016/j.neuroscience.2014.04.065. Epub 2014 May 9. PubMed PMID: 24814021; PubMed Central PMCID: PMC4122668.

7: Lopez de Diego H, Koradia V, Bond AD. Enantiotropically related polymorphs of gaboxadol hydrochloride. Acta Crystallogr C. 2013 Nov;69(Pt 11):1234-7. doi: 10.1107/S0108270113025961. Epub 2013 Oct 19. PubMed PMID: 24192165.

8: Broberg Ml, Holm R, Tønsberg H, Frølund S, Ewon KB, Nielsen Al, Brodin B, Jensen A, Kall MA, Christensen KV, Nielsen CU. Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. Br J Pharmacol. 2012 Oct;167(3):654-65. doi: 10.1111/j.1476-5381.2012.02030.x. PubMed PMID: 22577815; PubMed Central PMCID: PMC3449268.

9: Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, Korpi ER. GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons. J Neurosci. 2012 Apr 11;32(15):5310-20. doi: 10.1523/JNEUROSCI.4697-11.2012. PubMed PMID: 22496576.

10: Christensen T, Bétry C, Mnie-Filali O, Etievant A, Ebert B, Haddjeri N, Wiborg O. Synergistic antidepressant-like action of gaboxadol and escitalopram. Eur Neuropsychopharmacol. 2012 Oct;22(10):751-60. doi: 10.1016/j.euroneuro.2012.02.001. Epub 2012 Mar 9. PubMed PMID: 22406239.

11: Lundahl J, Deacon S, Maurice D, Staner L. EEG spectral power density profiles during NREM sleep for gaboxadol and zolpidem in patients with primary insomnia. J Psychopharmacol. 2012 Aug;26(8):1081-7. doi: 10.1177/0269881111424457. Epub 2011 Nov 5. PubMed PMID: 22057018.

12: Kasper S, Ebert B, Larsen K, Tonnoir B. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. Int J Neuropsychopharmacol. 2012 Jul;15(6):715-25. doi: 10.1017/S146114571100112X. Epub 2011 Oct 19. PubMed PMID: 22008735.

13: Ma J, Dijk DJ, Svetnik V, Tymofyeyev Y, Ray S, Walsh JK, Deacon S. EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women. J Clin Sleep Med. 2011 Oct 15;7(5):493-501A. doi: 10.5664/JCSM.1316. PubMed PMID: 22003345; PubMed Central PMCID: PMC3190849.

14: Dijk DJ, Stanley N, Lundahl J, Groeger JA, Legters A, Trap Huusom AK, Deacon S. Enhanced slow wave sleep and improved sleep maintenance after gaboxadol administration during seven nights of exposure to a traffic noise model of transient insomnia. J Psychopharmacol. 2012 Aug;26(8):1096-107. doi: 10.1177/0269881111421971. Epub 2011 Oct 13. PubMed PMID: 22002961.

15: Meera P, Wallner M, Otis TS. Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA(A) receptors. J Neurophysiol. 2011 Oct;106(4):2057-64. doi: 10.1152/jn.00450.2011. Epub 2011 Jul 27. PubMed PMID: 21795619; PubMed Central PMCID: PMC3191842.

16: Ramaker MJ, Ford MM, Fretwell AM, Finn DA. Alteration of ethanol drinking in mice via modulation of the GABA(A) receptor with ganaxolone, finasteride, and gaboxadol. Alcohol Clin Exp Res. 2011 Nov;35(11):1994-2007. doi: 10.1111/j.1530-0277.2011.01551.x. Epub 2011 Jun 7. PubMed PMID: 21649668; PubMed Central PMCID: PMC3173599.

17: Kueh SL, Dempster J, Head SI, Morley JW. Reduced postsynaptic GABAA receptor number and enhanced gaboxadol induced change in holding currents in Purkinje cells of the dystrophin-deficient mdx mouse. Neurobiol Dis. 2011 Sep;43(3):558-64. doi: 10.1016/j.nbd.2011.05.002. Epub 2011 May 13. PubMed PMID: 21601636.

18: Madsen KK, Ebert B, Clausen RP, Krogsgaard-Larsen P, Schousboe A, White HS. Selective GABA transporter inhibitors tiagabine and EF1502 exhibit mechanistic differences in their ability to modulate the ataxia and anticonvulsant action of the extrasynaptic GABA(A) receptor agonist gaboxadol. J Pharmacol Exp Ther. 2011 Jul;338(1):214-9. doi: 10.1124/jpet.111.179671. Epub 2011 Mar 30. PubMed PMID: 21450931; PubMed Central PMCID: PMC3126646.

19: Frølund S, Rapin N, Nielsen CU. Gaboxadol has affinity for the proton-coupled amino acid transporter 1, SLC36A1 (hPAT1)--A modelling approach to determine IC(50) values of the three ionic species of gaboxadol. Eur J Pharm Sci. 2011 Feb 14;42(3):192-8. doi: 10.1016/j.ejps.2010.11.009. Epub 2010 Nov 26. PubMed PMID: 21112392.

20: Svetnik V, Ferri R, Ray S, Ma J, Walsh JK, Snyder E, Ebert B, Deacon S. Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem. Sleep. 2010 Nov;33(11):1562-70. PubMed PMID: 21102998; PubMed Central PMCID: PMC2954706.